For the quarter ended September 2025, Sarepta Therapeutics (SRPT) reported revenue of $399.36 million, down 14.5% over the same period last year. EPS came in at -$0.13, compared to $0.62 in the year-ago quarter.
The reported revenue represents a surprise of +13.26% over the Zacks Consensus Estimate of $352.59 million. With the consensus EPS estimate being $0.01, the EPS surprise was -1400%.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Sarepta Therapeutics performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Revenues- Product, net: $370.04 million versus $332.97 million estimated by eight analysts on average. Compared to the year-ago quarter, this number represents a -13.9% change.
- Revenues- PMO Products: $238.54 million compared to the $224.56 million average estimate based on seven analysts. The reported number represents a change of -4.1% year over year.
- Revenues- Collaboration: $29.31 million compared to the $17.68 million average estimate based on seven analysts. The reported number represents a change of -21.6% year over year.
- Revenues- Product, net- ELEVIDYS: $131 million compared to the $107.41 million average estimate based on seven analysts. The reported number represents a change of -27.6% year over year.
View all Key Company Metrics for Sarepta Therapeutics here>>>
Shares of Sarepta Therapeutics have returned +5.1% over the past month versus the Zacks S&P 500 composite's +2.1% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Sarepta Therapeutics, Inc. (SRPT): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
